Compare Cassava Sciences Inc (FLNA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Toronto-Dominion Bank — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Toronto-Dominion Bank trades at $123.04 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 4198.5× Cassava Sciences Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TD | |
|---|---|---|
Market Cap | $47.75M | $200.48B |
Sector | Health | Financials |
52-Week High | $4.64 | $124.80 |
52-Week Low | $0.87 | $72.85 |
Enterprise Value | -$34.93M | — |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
TD trades at $121.08, down 0.19% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive given consistent earnings outperformance and a solid dividend, but risks include high debt levels and volatile cash flows. Analyst consensus is bullish with no sell ratings, supporting a favorable medium-term view amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
